Traders bought shares of Johnson & Johnson (NYSE:JNJ) on weakness during trading on Friday. $156.39 million flowed into the stock on the tick-up and $125.23 million flowed out of the stock on the tick-down, for a money net flow of $31.16 million into the stock. Of all equities tracked, Johnson & Johnson had the 25th highest net in-flow for the day. Johnson & Johnson traded down ($0.87) for the day and closed at $138.00

Several equities research analysts recently issued reports on JNJ shares. Credit Suisse Group started coverage on Johnson & Johnson in a research note on Thursday, July 20th. They issued an “outperform” rating and a $148.00 price target for the company. BTIG Research cut Johnson & Johnson from a “neutral” rating to a “sell” rating and set a $110.00 price target for the company. in a research note on Friday, July 21st. Atlantic Securities cut Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price target for the company. in a research note on Friday, July 21st. Alembic Global Advisors cut Johnson & Johnson from a “neutral” rating to an “underweight” rating in a research note on Friday, July 21st. Finally, Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Friday, July 21st. Four research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $143.70.

The firm has a market capitalization of $373,080.00, a price-to-earnings ratio of 19.54, a price-to-earnings-growth ratio of 2.83 and a beta of 0.82. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the prior year, the business posted $1.68 earnings per share. Johnson & Johnson’s quarterly revenue was up 10.3% on a year-over-year basis. equities analysts anticipate that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 12th. Shareholders of record on Tuesday, November 28th will be issued a dividend of $0.84 per share. The ex-dividend date is Monday, November 27th. This represents a $3.36 dividend on an annualized basis and a yield of 2.43%. Johnson & Johnson’s payout ratio is currently 58.33%.

A number of institutional investors have recently modified their holdings of the business. Vanguard Group Inc. boosted its position in shares of Johnson & Johnson by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock worth $26,517,661,000 after purchasing an additional 3,023,110 shares in the last quarter. BlackRock Inc. boosted its position in shares of Johnson & Johnson by 2.6% during the 2nd quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock worth $23,028,219,000 after purchasing an additional 4,332,612 shares in the last quarter. State Street Corp boosted its position in shares of Johnson & Johnson by 4.3% during the 1st quarter. State Street Corp now owns 160,223,321 shares of the company’s stock worth $19,955,806,000 after purchasing an additional 6,656,371 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Johnson & Johnson by 0.4% during the 3rd quarter. Bank of New York Mellon Corp now owns 36,594,054 shares of the company’s stock worth $4,757,593,000 after purchasing an additional 130,437 shares in the last quarter. Finally, FMR LLC boosted its position in shares of Johnson & Johnson by 5.9% during the 2nd quarter. FMR LLC now owns 27,237,648 shares of the company’s stock worth $3,603,268,000 after purchasing an additional 1,509,745 shares in the last quarter. Hedge funds and other institutional investors own 65.93% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Investors Buy Johnson & Johnson (JNJ) on Weakness” was originally published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another publication, it was copied illegally and republished in violation of international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dailypolitical.com/2017/11/17/investors-buy-johnson-johnson-jnj-on-weakness-9.html.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.